Shares of Natus Medical Inc. (NASDAQ:BABY) traded up 2.5% during trading on Thursday . The stock traded as high as $39.88 and last traded at $39.88, with a volume of 161,430 shares changing hands. The stock had previously closed at $38.91.

Separately, Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Thursday, July 7th.

The firm has a market cap of $1.29 billion and a PE ratio of 34.23. The stock’s 50-day moving average price is $39.11 and its 200 day moving average price is $36.07.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.03. The business earned $96 million during the quarter, compared to the consensus estimate of $92.71 million. During the same period in the prior year, the firm earned $0.34 EPS. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. Equities analysts predict that Natus Medical Inc. will post $1.68 EPS for the current year.

An institutional investor recently raised its position in Natus Medical stock. Morgan Stanley raised its position in shares of Natus Medical Inc. (NASDAQ:BABY) by 108.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 242,583 shares of the company’s stock after buying an additional 125,964 shares during the period. Morgan Stanley owned about 0.75% of Natus Medical worth $11,656,000 as of its most recent filing with the SEC.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.